GAM
BEAM icon

Gotham Asset Management’s Beam Therapeutics BEAM Stock Holding History

Gotham Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$368K Buy
+10,720
New +$324K ﹤0.01% 1590
2024
Q2 		– Sell
-14,932
Closed -$493K – 1421
2024
Q1 		$493K Buy
+14,932
New +$465K 0.01% 1058

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Gotham Asset Management's BEAM Position: Q2 2026 in Review

Gotham Asset Management opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 10,720 shares worth $368K. The stake represents ﹤0.01% of the portfolio and ranks #1590 among its holdings. This is a return to the name: Gotham Asset Management previously reported a position in BEAM as recently as Q1 2024.

Gotham Asset Management first reported a position in BEAM in Q1 2024 and has held it in 2 quarters since. The position peaked at $493K in Q1 2024. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Gotham Asset Management held 10,720 shares of Beam Therapeutics worth $368K as of Q2 2026.
  • Beam Therapeutics was a new Gotham Asset Management position in Q2 2026.
  • Beam Therapeutics made up ﹤0.01% of Gotham Asset Management's portfolio in Q2 2026, its #1590 holding.
  • Gotham Asset Management first reported a position in Beam Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • Gotham Asset Management's Beam Therapeutics position peaked at $493K in Q1 2024.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.